Skip to main content
. 2018 Feb 3;10:87–99. doi: 10.1016/j.molmet.2018.01.014

Figure 3.

Figure 3

A single injection of IRAB-A causes persistent reduction in glycemia and insulinemia in C57Bl/6 mice over two weeks. Mice were injected subcutaneously with IRAB-A or isotype control at the indicated dosages. Fed blood glucose was acutely monitored up to 8 h (A), and 21 days post-treatment (B). (C) Body weight (BW) measurements were collected from animals shown in panel (B). (D) Fed blood glucose and (E) plasma insulin were measured in IRAB-A treated mice out to day 14 in a separate cohort of animals. (F) Human serum IgG was measured for both IRAB-A and Isotype control over 14 days. Data in each panel represent mean ± SEM of 8 animals; *P < 0.05, †P < 0.01, ‡P < 0.001, §P < 0.0001. (G) Specific human IgG tissue staining in liver and (H) skeletal muscle was measured in IRAB-A treated mice (vi-x) and isotype control treated animals (i–v). Images are representative of results from 3 animals per time point.